Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 20-19 Tan BB06z CAR-T cells |
| Synonyms | |
| Therapy Description |
20-19 Tan BB06z CAR-T cells are T-cells engineered to express a bispecific chimeric antigen receptor (CAR) targeting CD20 and CD19 costimulatory 4-1BB and CD28 domains, which potentially induce cytokine production and inhibit of tumor growth (PMID: 34706886). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 20-19 Tan BB06z CAR-T cells | 20-19 Tan BB06z CAR T cells|20-19 Tan BB06z-CAR T-cells | CD19 Immune Cell Therapy 77 CD20 Immune Cell Therapy 17 | 20-19 Tan BB06z CAR-T cells are T-cells engineered to express a bispecific chimeric antigen receptor (CAR) targeting CD20 and CD19 costimulatory 4-1BB and CD28 domains, which potentially induce cytokine production and inhibit of tumor growth (PMID: 34706886). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07701889 | Phase I | 20-19 Tan BB06z CAR-T cells | Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies | Not yet recruiting | USA | 0 |